Skip to main content
ZBH
NYSE Industrial Applications And Services

Zimmer Biomet Q3 Sales $2.06B, Raises 2026 EPS and Organic Growth Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$96.8
Mkt Cap
$18.513B
52W Low
$79.12
52W High
$103.7
52W Position info
22% above low
Off High info
6.7% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

ZBH sits 22% above its 52-week low of $79.12.

Summary

Zimmer Biomet posted Q3 sales of $2.063 billion, up 3.1%, and adjusted EPS of $1.90, then raised full-year adjusted EPS guidance to $8.50-$8.60 and organic growth guidance to 3.0%-3.5%.


Key Events · Earnings and Guidance · ZBH

  • Q3 Sales Rise 3.1% to $2.063B

    Net sales of $2.063 billion increased 3.1% reported and 3.7% on a constant-currency basis; U.S. sales rose 3.6% to $1.206 billion.

  • Adjusted EPS Flat, GAAP EPS Down

    Adjusted diluted EPS was $1.90, consistent with the prior year period, while GAAP diluted EPS fell 13.8% to $1.00 on higher operating expenses.

  • Full-Year Guidance Raised

    Adjusted diluted EPS guidance lifted to $8.50-$8.60 from $8.47-$8.59; organic constant-currency revenue growth raised to 3.0%-3.5% from 2.25%-3.25%.

  • Strong Quarterly Cash Generation

    Operating cash flow of $560.0 million and free cash flow of $372.4 million in the quarter; nine-month free cash flow $926.5 million versus $803.8 million a year ago.


Analysis · ZBH · Industrial Applications And Services

The guidance raise is the key takeaway: management lifted full-year adjusted EPS to $8.50-$8.60 from $8.47-$8.59 and organic constant-currency revenue growth to 3.0%-3.5% from 2.25%-3.25%. Third-quarter sales grew 3.1% reported and 3.7% in constant currency to $2.063 billion, with adjusted diluted EPS of $1.90 flat versus a year ago while GAAP diluted EPS fell 13.8% to $1.00. Growth was broad-based in Hips, S.E.T. and Technology & Data, Bone Cement and Surgical, but Knees declined 3.1% reported, so the mix is uneven. Cash generation was strong at $560.0 million operating and $372.4 million free cash flow for the quarter, which supports the existing $1.5 billion buyback and dividend.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZBH was trading at $96.80 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $18.5B. The 52-week trading range was $79.12 to $103.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZBH - Latest Insights

ZBH
Nov 04, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $110.15
Real-time Price: $102.11 info
Change: -$8.04 (-7%) info
Market Cap: $19.321B info
ZBH
Nov 04, 2026, 12:16 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $111.76
Real-time Price: $102.11 info
Change: -$9.65 (-9%) info
Market Cap: $19.321B info
ZBH
Nov 04, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $96.80
Real-time Price: $102.11 info
Change: +$5.31 (+5%) info
Market Cap: $19.321B info
ZBH
Aug 05, 2026, 6:38 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $97.00
Real-time Price: $102.11 info
Change: +$5.11 (+5%) info
Market Cap: $19.321B info
ZBH
Aug 05, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $97.00
Real-time Price: $102.11 info
Change: +$5.11 (+5%) info
Market Cap: $19.321B info